Abstract: The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.
Abstract: The present invention relates to antibodies against SIRP? that are suitable for use in anti-cancer therapy. The invention further relates to the use of the anti-SIRP? antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with other anti-cancer therapeutics. The anti-SIRPalpha antibodies described are more specific than known anti-SIRPalpha antibodies, whereas they show excellent affinity for both SIRPalpha1 and SIRPalphaBIT. In one embodiment the anti-SIRPalpha antibodies do not bind to SIRPgamma. In a second embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPbeta1v1. In a third embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPeta1v2. In a fourth embodiment, the anti-SIRPalpha antibodies do not bind to SIRPbeta1v1.
Type:
Grant
Filed:
May 15, 2018
Date of Patent:
March 15, 2022
Assignee:
Byondis B.V.
Inventors:
Gijsbertus Franciscus Maria Verheijden, Gerard Rouwendal, Roland Jan Arends, Timo Kars Van Den Berg, Hanke Lottie Matlung, Katarina Franke
Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
Type:
Grant
Filed:
June 15, 2020
Date of Patent:
March 8, 2022
Assignee:
Baylor Research Institute
Inventors:
Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
Abstract: The present disclosure provides humanized anti-C1s antibodies. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the humanized anti-C1s antibodies; and host cells comprising the nucleic acids. The present disclosure provides compositions comprising the humanized anti-C1s antibodies. The present disclosure provides methods of use of the humanized anti-C1s antibodies.
Abstract: The present invention relates to immunoglobulins that specifically bind CD40L and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of CD40L and are safe.
Type:
Grant
Filed:
November 28, 2016
Date of Patent:
February 15, 2022
Assignee:
Ablynx N.V.
Inventors:
Els Pattyn, Ariƫlla Van de Sompel, Peter Meerts, Marie-Ange Buyse, Maarten Dewilde, Gerald Beste, Jaromir Vlach, Jonathan Hsu
Abstract: This application provides, inter alia, antibodies or antigen-binding fragments thereof, targeting OX40 expressed on injured tissues associated with multiple diseases. These OX40 antibodies, or antigen-binding fragments thereof, have a high affinity for OX40 and function as OX40 agonists or as OX40/OX40L antagonists. The antibodies and antigen-binding fragments are useful for treatment of human diseases, infections, and other conditions.
Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
Type:
Grant
Filed:
July 10, 2018
Date of Patent:
February 8, 2022
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh
Abstract: The present invention pertains to novel antibodies capable of binding to CD26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and/or preventing Graft-versus-Host Disease (GvHD), for use in treating Aplastic Anemia and/or for use in promoting engraftment after haematopoietic stem cell transplantation. Furthermore, the present invention provides pharmaceutical compositions comprising at least one antibody of the present invention, as well as provides a kit of parts.
Abstract: The present invention relates to novel anti-CD40 antibodies and a use thereof and, more specifically, provided are a pharmaceutical composition for treating or preventing autoimmune diseases and a composition for inhibiting immune rejection during organ transplantation, both compositions containing, as an active ingredient, novel anti-CD40 antibodies that specifically bind to a novel epitope of CD40. Novel anti-CD40 antibodies of the present invention directly target CD40, but not CD40 ligands, and block the signaling of CD40-CD154 without stimulating platelets so as to exhibit excellent antagonistic effects, thereby being expected to be usable as a preparation effective in the treatment of autoimmune diseases and the inhibition of organ transplantation rejection.
Abstract: Humanized antibody to a pathologically mislocated form of N-cadherin detects and eliminates cells that express the protein extracellularly. These cells are found in fibrotic conditions within heart, lung, and liver, as well as kidney, skin, and other organs effected by fibrosis. The antibody does not affect cells with normal, subcellular location of the protein.
Type:
Grant
Filed:
March 9, 2020
Date of Patent:
January 25, 2022
Assignee:
Duke University
Inventors:
Paul Ferrell, Salvatore Pizzo, Robin Bachelder
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
Type:
Grant
Filed:
May 24, 2018
Date of Patent:
January 11, 2022
Assignee:
Bristol-Myers Squibb Company
Inventors:
Aaron Yamniuk, Mary Struthers, Suzanne J. Suchard
Abstract: The present disclosure relates to, inter alia, a method of treating age-related macular degeneration (AMD) in a patient, comprising administering an effective amount of a C5 inhibitor or a C5a inhibitor.
Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
Inventors:
Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
Abstract: Provided are antibodies and antigen-binding fragments thereof that bind specifically to human complement factor C2 and are capable of inhibiting activation of the classical and lectin pathways of the complement system. The antibodies and antigen-binding fragment exhibit improved manufacturability, pharmacokinetics, and antigen sweeping. Also provided are pharmaceutical compositions comprising the antibodies and antigen-binding fragments, nucleic acids and vectors encoding the antibodies and antigen-binding fragments, host cells comprising the nucleic acids or vectors, and methods of making and using the antibodies and antigen-binding fragments. The antibodies and antigen-binding fragments can be used to inhibit the classical pathway of complement activation in a subject, e.g., a human. The antibodies and antigen-binding fragments can also be used to inhibit the lectin pathway of complement activation in a subject, e.g., a human.
Abstract: Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.
Type:
Grant
Filed:
November 20, 2018
Date of Patent:
October 5, 2021
Assignee:
Duke University
Inventors:
Edward F. Patz, Jr., Michael J. Campa, Elizabeth Gottlin, Barton F. Haynes, Hua-Xin Liao, M. Anthony Moody
Abstract: The present disclosure provides binding agents, such as antibodies (including single chain variable fragments), that specifically bind complement component C3, including human C3, compositions comprising same, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising same.
Type:
Grant
Filed:
April 1, 2019
Date of Patent:
October 5, 2021
Assignee:
NGM Biopharmaceuticals, Inc.
Inventors:
Dana Yen Mei Duey, Zhonghao Liu, Jie Tang, Yan Wang, Yiyuan Yin, Wenwu Zhai, Jared Martin Higbee